Skin Cancer (Nonmelanoma)

The study, published in Dermato, showed that 92% of NMSC tumors showed measurable changes in depth of invasion from one image to the next.

To improve overall outcomes for patients with large basal cell carcinomas, it has been beneficial to employ the use of vismodegib as a neoadjuvant and/or adjuvant treatment.

Jacob Scott, MD, president and chairman of DaRT, shares highlights of the guidelines and what he hopes clinicians can glean from them.

Margins < 1 mm also do not increase the risk of cutaneous squamous cell carcinoma recurrence risk if the galea aponeurotica is not involved.

The guidelines for BCC and SCC treatment with IGSRT detail diagnosis, staging, contraindications, protocols, and emphasize the essential role of a multidisciplinary team.

From our March cover feature: Vulnerable populations such as the prison population should have access to Mohs surgery to prevent the increased risk of morbidity and mortality from skin cancer.

New data on the devices will be available at the 2024 American Academy of Dermatology Annual Meeting.

In this study, researchers treated 37 basal cell carcinoma (BCC) lesions from 30 patients, with follow-ups at 5 time points after baseline examination.

SKNJCT-003 is expected to enroll up to 60 patients.

The study evaluated the efficacy of AIV001 in superficial, nodular, and mixed BCC tumors.

One of the specific areas of focus will be non-melanoma skin cancer.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Image-Guided Superficial Radiation Therapy kills cancer cells without surgery.

Collaboration between dermatologists and gynecologists can improve patient quality of life and outcomes in vSCC treatment.

Click here to answer this week's poll.

In a murine model, application of PALA in topical fashion led to reductions in tumor grades and numbers.

Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.

Principal investigator Jason Luke, MD, discusses what the new data means for melanoma treatment moving forward.

Emily Ruiz, MD and Todd Schlesinger, MD discuss treatment options for locally advanced basal cell carcinoma, such as immunotherapy and surgery.

Drs Justine Cohen and Brent Moody provide their key takeaways and panel discussion highlights related to the management of patients with basal cell carcinoma.

An expert in dermatology shares her insights into the duration of treatment and dose adjustments for systemic treatments in patients with basal cell carcinoma.

Dr Justine Cohen discusses her approach to systemic treatment selection in her patients with basal cell carcinoma; highlighting the importance of individualizing the treatment plan.

Justine Cohen, DO and Brent Moody M.D., F.A.C.P., F.A.A.D, comment on which patients would be appropriate for non-surgical treatment options in the management of their basal cell carcinoma.

Click here to answer this week's poll.

Catch up on the innovative pearls shared at the 2023 American College of Mohs Surgery including strategies to enhace the patient experience, the role artificial intelligence plays in dermatologic care, and more.